Zacks Investment Research downgraded shares of Hikma Pharmaceuticals Plc (OTC:HKMPF) from a hold rating to a sell rating in a report published on Friday morning.
According to Zacks, “Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. “
A number of other research analysts also recently issued reports on the company. Goldman Sachs Group, Inc. (The) downgraded Hikma Pharmaceuticals Plc from a buy rating to a neutral rating in a research note on Tuesday, August 22nd. Morgan Stanley reissued an equal weight rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, August 8th. ValuEngine raised Hikma Pharmaceuticals Plc from a hold rating to a buy rating in a research note on Thursday, July 27th. Finally, Jefferies Group LLC raised Hikma Pharmaceuticals Plc from an underperform rating to a hold rating in a research note on Monday, August 21st. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the stock. Hikma Pharmaceuticals Plc currently has a consensus rating of Hold.
Shares of Hikma Pharmaceuticals Plc (OTC HKMPF) opened at $14.94 on Friday. Hikma Pharmaceuticals Plc has a 52-week low of $14.94 and a 52-week high of $27.50.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://ledgergazette.com/2017/11/13/hikma-pharmaceuticals-plc-hkmpf-cut-to-sell-at-zacks-investment-research.html.
About Hikma Pharmaceuticals Plc
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products in solid, semi-solid, liquid, and injectable final dosage forms worldwide. It operates through three segments: Branded, Injectables, and Generic. The Branded segment offers 377 products in 1,125 dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system (CNS), gastro-intestinal, oncology, respiratory, and miscellaneous therapeutic areas.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Hikma Pharmaceuticals Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals Plc and related companies with MarketBeat.com's FREE daily email newsletter.